We are live on ! Find out more
VIA

Vident Investment Advisory Portfolio holdings

AUM $2.9B
1-Year Est. Return 24.67%
This Fund
S&P 500
This Quarter Est. Return
+5.51%
1 Year Est. Return
+24.67%
3 Year Est. Return
+82.63%
5 Year Est. Return
+113.33%
10 Year Est. Return
AUM
$1.01B
AUM Growth
+$183M
Cap. Flow
+$156M
Cap. Flow %
15.54%
Top 10 Hldgs %
13.85%
Holding
515
New
136
Increased
129
Reduced
153
Closed
95
Name Market Value Portfolio Weight Shares or Principal Change
in Stake
Capital Flow
AMZN icon
276
Amazon
AMZN
$2.96T
$1.65M 0.16%
37,140
-5,260
-12% -$219K
ROG icon
277
Rogers Corp
ROG
$2.4B
$1.64M 0.16%
19,101
-11,112
-37% -$908K
CHTR icon
278
Charter Communications
CHTR
$18.3B
$1.54M 0.15%
4,719
+2,424
+106% +$772K
DO
279
DELISTED
Diamond Offshore Drilling
DO
$1.53M 0.15%
91,532
-10,236
-10% -$174K
CAL icon
280
Caleres
CAL
$485M
$1.53M 0.15%
+57,788
New +$1.74M
CSGS
281
DELISTED
CSG Systems International
CSGS
$1.49M 0.15%
39,440
-1,845
-4% -$78.2K
KCG
282
DELISTED
KCG Holdings, Inc.
KCG
$1.46M 0.14%
81,801
-40,020
-33% -$595K
KITE
283
DELISTED
Kite Pharma, Inc.
KITE
$1.41M 0.14%
17,960
+2,992
+20% +$185K
MSFT icon
284
Microsoft
MSFT
$3.71T
$1.37M 0.14%
20,776
+279
+1% +$17.9K
IOSP icon
285
Innospec
IOSP
$2.26B
$1.35M 0.13%
20,829
-9,770
-32% -$654K
DSU icon
286
BlackRock Debt Strategies Fund
DSU
$597M
$1.34M 0.13%
+116,316
New +$1.34M
SPTN
287
DELISTED
SpartanNash
SPTN
$1.34M 0.13%
38,288
-2,474
-6% -$90.7K
CTMX icon
288
CytomX Therapeutics
CTMX
$749M
$1.31M 0.13%
75,924
+12,652
+20% +$167K
MOH icon
289
Molina Healthcare
MOH
$10.2B
$1.31M 0.13%
28,740
-8,406
-23% -$440K
GES
290
DELISTED
Guess Inc
GES
$1.28M 0.13%
115,259
+365
+0.3% +$4.49K
ADAP
291
DELISTED
Adaptimmune Therapeutics
ADAP
$1.28M 0.13%
232,641
+38,772
+20% +$170K
XHR
292
Xenia Hotels & Resorts
XHR
$1.8B
$1.25M 0.12%
+73,459
New +$1.32M
INCY icon
293
Incyte
INCY
$24.4B
$1.23M 0.12%
7,729
+1,664
+27% +$212K
CLLS
294
Cellectis
CLLS
$284M
$1.22M 0.12%
50,994
+8,496
+20% +$178K
ATRA icon
295
Atara Biotherapeutics
ATRA
$74.3M
$1.14M 0.11%
2,227
+371
+20% +$154K
SCHE icon
296
Schwab Emerging Markets Equity ETF
SCHE
$12.9B
$1.14M 0.11%
47,400
-51,700
-52% -$1.2M
BLUE
297
DELISTED
bluebird bio
BLUE
$1.13M 0.11%
962
+160
+20% +$163K
SVXY icon
298
ProShares Short VIX Short-Term Futures ETF
SVXY
$207M
$1.13M 0.11%
8,000
+2,200
+38% +$273K
EXPR
299
DELISTED
Express, Inc.
EXPR
$1.13M 0.11%
6,177
-152
-2% -$31.4K
AMGN icon
300
Amgen
AMGN
$221B
$1.12M 0.11%
6,821
-1,499
-18% -$249K

Similar funds

Vident Investment Advisory's Q1 2017 Portfolio in Review

As of Q1 2017, Vident Investment Advisory held 515 positions worth $1.01B, up 22% from $824M the previous quarter. Its ten largest holdings account for 14% of the portfolio.

Vident Investment Advisory deployed $156M of net new capital in Q1 2017, opening 136 new positions and adding to 129 existing holdings. Its largest new stake was Eaton Vance Tax-Advantaged Global Dividend Income Fund: 428,405 shares worth $6.71M.

By sector, the portfolio is most concentrated in Technology at 17% of assets, up from 15% a quarter earlier, followed by Industrials and Financials.

On the sell side, the largest reduction was Virtus Convertible & Income Fund, an estimated $3.84M trimmed.

  • Vident Investment Advisory's largest Q1 2017 buy was Eaton Vance Tax-Advantaged Global Dividend Income Fund: 428,405 shares worth $6.71M.
  • Vident Investment Advisory added most to State Street SPDR S&P 500 ETF Trust in Q1 2017, an estimated $26.6M increase.
  • Vident Investment Advisory's biggest Q1 2017 reduction was Virtus Convertible & Income Fund, cutting an estimated $3.84M.
  • Vident Investment Advisory fully exited Royce Value Trust in Q1 2017, selling an estimated $5.55M.
  • Vident Investment Advisory's ten largest holdings make up 14% of its $1.01B portfolio in Q1 2017.
  • Vident Investment Advisory opened 136 new positions and closed 95 in Q1 2017.
  • Vident Investment Advisory's portfolio value rose 22% quarter-over-quarter to $1.01B.

Based on Vident Investment Advisory's 13F filing for Q1 2017, filed 10 May 2017.